The Philippine Wound Care Society is a non profit, non stock, SEC registered organization and the organization held its 1st regional meeting February 26-27, 2015 at Cebu City Philippines.
Pasadena, CA (InvisiDerm) March 12, 2015
The Philippine Wound Care Society is a non profit, non stock, SEC registered organization. It was founded on September 09, 2009 with the purpose of improving the wound management in the Philippines through education. The society which is composed of physicians from different specialty groups and allied services (wound care nurse, physical therapy) brings together professionals involved in wound care.
The organization held its 1st regional meeting February 26-27, 2015 at Cebu City Philippines. InvisiDerm's CEO, Norbert Kiss and Senior Sales and Marketing Manager, Jennifer Rose Boadilla were invited by the President of the organization, Dr. Martin Anthony A. Villa and got the chance to meet some of the most influential cardiovascular and wound care KOLs at the said event.
The event was professional and had overwhelming participation exceeding the initially registered numbers. The speakers and their presentations were high quality and informative showcasing the latest in technologies and approaches to wound management.
We are glad to announce that InvisiDerm has secured some of the most influential cardiovascular and wound care KOLs from Taiwan, Singapore, Japan, Korea, Philippines and a few other countries via strategic relationships at this Philippine Wound Care Society Regional Meeting. In addition, a protocol for a comprehensive multicenter study coupled with diagnostics for diabetic foot wound healing on hundreds of subjects at leading hospitals, and an academic level study into the biochemical properties of D'OXYVA in wound healing, and a study for erectile dysfunction in diabetics was finalized, agreed and initiated with several KOLs based on the successful pilot study conducted by Dr. Harikrishna R. Nair at Hospital Kuala Lumpur, Malaysia. The quality of life benefits for patients such as significantly improved sleeping, eating, mood and pain makes D'OXYVA a distinct winner besides being noninvasive and fast without negative side effects. Furthermore, InvisiDerm has met regional directors of several leading wound care products multinationals and their distributors for in-depth private discussions about business models and development challenges across Asia. InvisiDerm is clearly a leader in a number of aspects if not most. Special thanks to the team at Getz Bros. Philippines for their warm hospitality.
For More Information
Please visit http://www.MyInvisiDerm.com and send your general inquiries via the Contact Us page, or for specific inquiries contact InvisiDerm Public Relations at pr(at)myinvisiderm(dot)com or by phone at +1(626) 817-6685.
No association or collaboration whatsoever is implied or expressed between InvisiDerm Healthcare and the Philippine Wound Care Society in the following content. The opinions and statements found herein, expressed or implied constitute the sole private initiatives of InvisiDerm Healthcare and InvisiDerm Healthcare takes full responsibility for their accuracy and completeness.
This press release may contain forward-looking information. This includes, or may be based upon, estimates, forecasts and statements as to management’s expectations with respect to, among other things, the quality of the products of InvisiDerm Healthcare, its resources, progress in development, demand and market outlook for noninvasive transdermal delivery medical devices. Forward-looking information is based on the opinions and estimates of management at the date the information is given and is subject to a variety of risks and uncertainties that could cause actual events or results to differ materially from those initially projected. These factors include the inherent risks involved in the launch of a new medical device, innovation and market acceptance uncertainties, fluctuating components and other advanced material prices, new federal or state governmental regulations, the possibility of project cost overruns or unanticipated costs and expenses, uncertainties relating to the availability and costs of financing needed in the future and other factors. The forward-looking information contained herein is given as of the date hereof and InvisiDerm Healthcare assumes no responsibility to update or revise such information to reflect new events or circumstances, except as required by law. InvisiDerm Healthcare makes no representations or warranties as to the accuracy or completeness of this press release and shall have no liability for any representations (expressed or implied) for any statement made herein, or for any omission from this press release.